Phase 3 trial in 144 patients aged 2-21 with Dravet syndrome: adjunctive soticlestat did not significantly reduce convulsive seizures vs placebo (median change -22.16% vs -8.64%; P=.061); 50% responder rate 27.4% vs 9.9% (secondary, nominal).
RCTn = 144
Sullivan et al. Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome